Biological Markers in Tears May Diagnose PD
By LabMedica International staff writers Posted on 15 Mar 2018 |

Image: The Schirmer’s test is an invasive filter paper strip folded over the lower lid to absorb the tear film for five minutes. The tears collected on the Schirmer’s strips can be analyzed for biomarkers (Photo courtesy of Innovative Eye Care).
Parkinson's disease is a progressive disorder that kills brain cells that produce dopamine, which is a chemical messenger important for the control of movement. The main symptoms of Parkinson's include slowness of movement, tremors, rigidity, and difficulty maintaining balance and coordination.
Tear samples from individuals with Parkinson's disease (PD) had different levels of a protein linked to the disease than those who did not have it. Such a marker could be very useful in helping to diagnose, and perhaps even treat Parkinson's because the disease can begin many years before its symptoms appear.
Scientists at the University of Southern California (Los Angeles, CA, USA) and their colleagues compared tear samples from 55 PD patients of varying severity and 27 age- and gender-matched non-PD controls were collected and pooled from both eyes for analysis of alpha synuclein, CC chemokine ligand 2 (CCL-2) and DJ-1 (Parkinson’s disease protein 7) using a Human magnetic Luminex assay kit and analysis of oligomeric alpha-synuclein using an Human alpha-synuclein oligo enzyme-linked immunosorbent assay (ELISA) kit, respectively.
The team revealed that total alpha-synuclein decreased significantly in PD patients (423.12 ± 52.6 pg/mg tear protein) relative to healthy controls (703.61 ± 136.4 pg/mg tear protein) in tears from patients acquired from Schirmer’s strips taken during an anesthetized Schirmer’s test. Oligomeric alpha-synuclein increased significantly in PD patients (1.45 ± 0.31 ng/mg tear protein) relative to controls (0.27 ± 0.07 ng/mg tear protein). While detectable in tears, neither CCL-2 nor DJ-1 varied between PD patients and non-PD controls.
While it is not yet clear how Parkinson's disease kills brain cells, scientists have discovered that toxic protein deposits known as Lewy bodies are often present in many brain cells of people with the disease. These deposits contain clusters of proteins that have not folded correctly. A major component of Lewy bodies is an oligomeric form of the protein alpha-synuclein. The oligomeric form of a protein comprises several repeats of the protein's essential amino acids, but not as many as the polymeric form. An author of a recently published study of alpha-synuclein in Parkinson's has suggested that the oligomeric protein's ability to "disrupt the integrity of the membrane" might be a key step in the process that ultimately kills the cell.
Mark F. Lew, MD, a professor of Neurology and lead investigator in the study, said, “We believe our study is the first to show that tears may be a reliable, inexpensive, and noninvasive biological marker of Parkinson's disease.” The study will be presented at the 70th annual meeting of the American Academy of Neurology, which will be held April 21-27, 2018, in Los Angeles, CA, USA.
Related Links:
University of Southern California
Tear samples from individuals with Parkinson's disease (PD) had different levels of a protein linked to the disease than those who did not have it. Such a marker could be very useful in helping to diagnose, and perhaps even treat Parkinson's because the disease can begin many years before its symptoms appear.
Scientists at the University of Southern California (Los Angeles, CA, USA) and their colleagues compared tear samples from 55 PD patients of varying severity and 27 age- and gender-matched non-PD controls were collected and pooled from both eyes for analysis of alpha synuclein, CC chemokine ligand 2 (CCL-2) and DJ-1 (Parkinson’s disease protein 7) using a Human magnetic Luminex assay kit and analysis of oligomeric alpha-synuclein using an Human alpha-synuclein oligo enzyme-linked immunosorbent assay (ELISA) kit, respectively.
The team revealed that total alpha-synuclein decreased significantly in PD patients (423.12 ± 52.6 pg/mg tear protein) relative to healthy controls (703.61 ± 136.4 pg/mg tear protein) in tears from patients acquired from Schirmer’s strips taken during an anesthetized Schirmer’s test. Oligomeric alpha-synuclein increased significantly in PD patients (1.45 ± 0.31 ng/mg tear protein) relative to controls (0.27 ± 0.07 ng/mg tear protein). While detectable in tears, neither CCL-2 nor DJ-1 varied between PD patients and non-PD controls.
While it is not yet clear how Parkinson's disease kills brain cells, scientists have discovered that toxic protein deposits known as Lewy bodies are often present in many brain cells of people with the disease. These deposits contain clusters of proteins that have not folded correctly. A major component of Lewy bodies is an oligomeric form of the protein alpha-synuclein. The oligomeric form of a protein comprises several repeats of the protein's essential amino acids, but not as many as the polymeric form. An author of a recently published study of alpha-synuclein in Parkinson's has suggested that the oligomeric protein's ability to "disrupt the integrity of the membrane" might be a key step in the process that ultimately kills the cell.
Mark F. Lew, MD, a professor of Neurology and lead investigator in the study, said, “We believe our study is the first to show that tears may be a reliable, inexpensive, and noninvasive biological marker of Parkinson's disease.” The study will be presented at the 70th annual meeting of the American Academy of Neurology, which will be held April 21-27, 2018, in Los Angeles, CA, USA.
Related Links:
University of Southern California
Latest Clinical Chem. News
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Channels
Molecular Diagnostics
view channel
Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
Neutrophils, once believed to be uniform in nature, have been discovered to exhibit significant diversity. These immune cells, which play a crucial role in fighting infections, are also implicated in autoimmune... Read more
First-of-its-Kind Blood Test Detects Trauma-Related Diseases
In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more